First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

CONCLUSIONS: Based on population-based data in patients with metastatic PDAC, treatment predominantly consists of FOLFIRINOX in the first line and gemcitabine with or without nab-paclitaxel in the second line. FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel.PMID:34450595 | DOI:10.6004/jnccn.2021.7028

Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Esther N Pijnappel Willemieke P M Dijksterhuis Lydia G van der Geest Judith de Vos-Geelen Jan Willem B de Groot Marjolein Y V Homs Geert-Jan Creemers Nadia Haj Mohammad Marc G Besselink Hanneke W M van Laarhoven Johanna W Wilmink Dutch Pancreatic Cancer G Source Type: research